ADMA Biologics (ADMA) Stock Price
ADMA Biologics Price
Over the last 13 years ADMA Biologics grew revenue by 60.2% annually, reaching 510.17 M USD. For ADMA Biologics, the net margin of 28.8% is up versus -88.5% a few years ago. The consensus 12-month price target for ADMA Biologics is 18.00 USD, about 69.3% above where the stock trades today. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.
ADMA Biologics stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
ADMA Biologics business model & stock analysis
Frequently asked questions about ADMA Biologics
ADMA Biologics Inc operates as a biopharmaceutical company. The company develops and produces specialty plasma-derived products for the treatment of immune deficiencies and infectious diseases. ADMA Biologics focuses on the production and marketing of its hyperimmune globulin products, which are used to treat various medical conditions. With its emphasis on specialty plasma-derived products, ADMA Biologics Inc aims to improve patient outcomes and address unmet medical needs.
ADMA Biologics Inc is primarily active in the biopharmaceutical and healthcare industries.
The main competitors of ADMA Biologics Inc in the market include companies such as Grifols, CSL Ltd, and Octapharma.
ADMA Biologics Inc is a biopharmaceutical company specializing in the development and commercialization of plasma-derived products for the treatment of immune deficiencies and other infectious diseases. Founded in 2004, ADMA Biologics has evolved into a leading player in the immunoglobulin market. The company operates its own plasma collection centers and has a state-of-the-art fractionation facility located in Boca Raton, Florida. ADMA Biologics strives to deliver high-quality, plasma-derived products to patients with unmet medical needs. With a strong commitment to innovation and excellence, ADMA Biologics continues to expand its product pipeline and market presence, aiming to improve the lives of patients worldwide.
ADMA Biologics Inc has achieved significant milestones in its journey. The company has successfully gained FDA approval for its first plasma-derived biologic, RI-002™. In addition, they have expanded their product portfolio by launching BIVIGAM®, a treatment for primary humoral immunodeficiency, and ASCENIV™, a hyperimmune globulin. ADMA Biologics Inc also received FDA approval for acquisition of their BOC facility in Boca Raton, Florida, which has resulted in increased plasma collection capacity. These milestones have strengthened ADMA Biologics Inc's position in the market and reflect their commitment to providing innovative solutions and expanding their reach in the biopharmaceutical industry.
ADMA Biologics Inc is primarily present in the United States.
ADMA Biologics Inc represents a strong commitment to developing and delivering innovative plasma-derived products for the treatment of immune deficiencies and other infectious diseases. The company's corporate philosophy centers around maximizing patient access to life-saving therapies, ensuring product quality and safety, and fostering a culture of excellence in research and development. ADMA Biologics Inc values integrity, collaboration, and dedication to improving patient outcomes. Through its cutting-edge technologies and strategic partnerships, the company strives to address unmet medical needs and make a positive impact on global healthcare. ADMA Biologics Inc is dedicated to providing high-quality products and delivering value to patients, healthcare professionals, and stakeholders.
Analysts currently set an average price target of 18.67 USD for the ADMA Biologics stock (median: 18.00 USD), implying +75.6 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the ADMA Biologics stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect ADMA Biologics to generate revenue of 535.35 M USD and earnings per share of 0.80 USD.
Converted at the current exchange rate, the ADMA Biologics share trades at 9.48 EUR (10.64 USD).
The ADMA Biologics share (ADMA) is listed on 1 stock exchanges, including: NASDAQ (ADMA).
ADMA Biologics Inc is a US biopharmaceutical company focused on the development of intravenous immunoglobulins (IVIG). The company was founded in 2004 and is headquartered in Ramsey, New Jersey. ADMA Biologics Inc's business model is based on the production and marketing of IVIG products for the treatment of primary immune deficiency diseases (PID). The company is divided into three business segments: manufacturing, sales and marketing of IVIG products, pipeline product development, and management of licenses and patents. ADMA Biologics Inc currently produces two IVIG products: BIVIGAM and ASCENIV. BIVIGAM is used to treat primary immune deficiency diseases, while ASCENIV is administered through intravenous push-injection. ADMA Biologics Inc is also working on developing additional IVIG products, and holds licenses and patents in the field of plasma proteins and related technologies. In summary, ADMA Biologics Inc's business model revolves around the production and marketing of IVIG products for the treatment of primary immune deficiency diseases. The company is involved in manufacturing, sales, and marketing of these products, as well as the development of new pipeline products. They also hold licenses and patents in the field of plasma proteins and related technologies.
The expected revenue of ADMA Biologics is 535.35 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of ADMA Biologics is 195.11 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of ADMA Biologics is currently 13.29. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the ADMA Biologics stock.
The price-to-sales ratio (P/S) of ADMA Biologics is currently 4.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the ADMA Biologics stock.
The Eulerpool Quality Score for ADMA Biologics is 7/10.
The ISIN of ADMA Biologics is US0008991046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of ADMA Biologics is A12FAG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of ADMA Biologics is ADMA. The ticker symbol is used to trade ADMA Biologics shares on the stock exchange.
ADMA Biologics stock
ADMA Biologics Peer Group
ADMA Biologics Ticker
ADMA Biologics FIGI
All fundamentals and in-depth analysis of ADMA Biologics
Our stock analysis for ADMA Biologics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADMA Biologics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.